LOGIN  |  REGISTER
Terns Pharmaceuticals

Latest Medical Device News

Inspira™ Technologies Collaborates With Zriha Medical To Launch Cutting-Edge Production Line

January 17
Last Trade: 1.06 0.00 0.00

RA'ANANA, ISRAEL, Jan. 17, 2025 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) ("Inspira" or the "Company"), a leader in life-support technology innovation, has announced that the Company is establishing a dedicated production line for a crucial component of its innovative respiratory support system, in collaboration with Zriha Medical Ltd ("Zriha Medical"), a leading international manufacturer specializing in...Read more


Late-breaking data presented at AF Symposium 2025 highlight key Boston Scientific therapies for management of patients with atrial fibrillation

January 16
Last Trade: 98.66 0.49 0.50

First phase of ADVANTAGE AF clinical trial achieves safety and effectiveness endpoints for treatment of drug-resistant, symptomatic, persistent atrial fibrillation with the FARAPULSE™ Pulsed Field Ablation System Sub-analysis from OPTION clinical trial highlights consistent safety and efficacy outcomes with the WATCHMAN FLX™ Left Atrial Appendage Closure Device post cardiac ablation in both concomitant and sequential...Read more


Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemaSeed® for Female Infertility Treatment

January 16
Last Trade: 1.11 0.00 0.00

FemaSeed® patent application provides additional coverage for Femasys’ therapeutic option for women seeking infertility solution ATLANTA, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces the United States Patent and...Read more


United Arab Emirates Ministry of Health and Prevention Approves Biomerica’s Fortel® PSA Screening Test to Detect an Early Sign of Prostate Cancer

January 16
Last Trade: 0.64 -0.07 -9.35

10-Minute PSA Test for Early Detection of Prostate Specific Antigen (PSA), an Early Warning Sign of Prostate Cancer Prostate Cancer: The Second Most Common Cancer in Men Globally IRVINE, Calif., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of innovative diagnostic solutions, is proud to announce that its Fortel® Prostate Specific Antigen (PSA) Screening Test has received approval from the...Read more


Masimo Announces Select Preliminary 2024 Financial Results and 2025 Guidance

January 16
Last Trade: 172.29 2.35 1.38

Complete fourth quarter and full-year 2024 financial results will be announced on Tuesday, February 25, 2025 IRVINE, Calif. / Jan 16, 2025 / Business Wire / Masimo Corporation (Nasdaq: MASI) today announced select preliminary financial results for the fourth quarter and full-year ended December 28, 2024 and provided estimates for its full-year 2025 guidance. Preliminary Fourth Quarter 2024 Financial Results: Consolidated revenue is...Read more


Predictive Oncology Announces Planned European Launch of its ChemoFx® Treatment Selection Marker and Tumor Profiling Assay

January 16
Last Trade: 1.21 -0.13 -9.70

Initial plans target European clinical trials while providing standard testing to clinicians for individual patients There are an estimated 250,000 gynecologic cancers diagnosed annually across Europe PITTSBURGH, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, today announced plans to launch its validated flagship live cell ChemoFx® drug response assay in Europe...Read more


Intuitive Surgical Announces Preliminary Fourth Quarter and Full Year 2024 Results

January 15
Last Trade: 592.64 8.56 1.47

SUNNYVALE, Calif., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Intuitive (the “Company”) (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced certain unaudited preliminary fourth quarter and full year 2024 financial results ahead of its presentation at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025. Financial and Operational Highlights Fourth...Read more


Cytek Biosciences Announces Preliminary Full Year 2024 Revenue Results

January 15
Last Trade: 5.46 -0.03 -0.55

FREMONT, Calif., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced preliminary, unaudited revenue results for the full year ended December 31, 2024. Cytek expects its full year revenue for 2024 to be between $200 million and $201 million, representing 4% growth over Cytek’s 2023 revenue of $193.0 million. This included a negative foreign exchange impact of...Read more


Becton Dickinson Boosts U.S. Manufacturing of Critical Medical Devices

January 15
Last Trade: 237.38 1.08 0.46

FRANKLIN LAKES, N.J., Jan. 15, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced additional investments in its U.S. manufacturing network to add capacity for critical medical devices, including syringes, needles and IV catheters, to meet the ongoing needs of the nation's health care system. As part of the company's 2024 investment of more than $10...Read more


Biomerica Reports Second Quarter Fiscal 2025 Financial Results

January 15
Last Trade: 0.64 -0.07 -9.35

Total Revenue Increases 5% Year-Over-Year Achieves Sustained Revenue Growth, Improved Gross Margins, and Significant Cost Savings IRVINE, Calif., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical diagnostic and therapeutic products today reported financial results for the second quarter of fiscal 2025 ended November 30, 2024. Key Highlights: Direct-to-Consumer...Read more


Rapid Micro Biosystems Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Revenue

January 14
Last Trade: 1.23 0.03 2.50

Fourth quarter 2024 total revenue expected to be a record at approximately $8.2 million, representing growth of approximately 30% compared to the prior-year period. Fourth quarter 2024 recurring revenue expected to be approximately $4.2 million, representing growth of approximately 27% compared to the prior-year period. Full year 2024 total revenue expected to be approximately $28.1 million, representing growth of approximately...Read more


Glaukos Announces Positive Clinical Updates for its iDose® Sustained-Release Procedural Pharmaceutical Platform

January 14
Last Trade: 156.39 -0.12 -0.08

ALISO VIEJO, Calif. / Jan 14, 2025 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced several positive clinical updates for its iDose® sustained-release procedural pharmaceutical platform, including: In a new 36-month follow-up analysis of its two Phase 3 pivotal...Read more


908 Devices Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results

January 14
Last Trade: 2.98 0.08 2.76

Full year 2024 reported revenue growth of at least 15% compared to 2023 BOSTON / Jan 14, 2025 / Business Wire / 908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, today announced preliminary unaudited financial results for the quarter and full year ended December 31, 2024. Preliminary unaudited revenue for the fourth quarter of 2024 is expected to be approximately $17.2...Read more


Inspira Technologies Unveils Modular Configuration for Revolutionary VORTX™ Blood Oxygenation Delivery Technology

January 14
Last Trade: 1.06 0.00 0.00

The technology has the potential to provide life-saving support for the approximately 20 million ICU patients with respiratory failure annually RA'ANANA, Israel, Jan. 14, 2025 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) ("Inspira" or the "Company"), a leader in life-support technology innovation, is proud to announce the development of a modular configuration for its groundbreaking VORTX blood...Read more


Sight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2024 Financial Highlights

January 14
Last Trade: 2.83 -0.01 -0.35

MENLO PARK, Calif., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients' lives, today reported select preliminary, unaudited financial highlights for the fourth quarter and full year ended December 31, 2024. Select Preliminary Financial...Read more


Elutia Announces Full Launch of EluPro Following Strong Initial Demand

January 14
Last Trade: 3.20 -0.01 -0.31

First FDA-Cleared Antibiotic-Eluting BioEnvelope Now Available in U.S. for Implantable Pacemakers, Defibrillators, and Neurostimulators SILVER SPRING, Md., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT), a pioneer in drug-eluting biomatrix technologies, announced the U.S. commercial launch of EluPro™, the first and only FDA-cleared antibiotic-eluting biomatrix designed for use with cardiac implantable electronic devices...Read more


Iridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2024

January 14
Last Trade: 1.66 0.03 1.84

MOUNTAIN VIEW, Calif., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems and delivery devices for the treatment of glaucoma and retinal diseases, today announced preliminary unaudited operational and financial results for the fourth quarter and full year ended December 28, 2024. Fourth Quarter 2024 Results The Company’s strategic...Read more


Allurion Technologies Announces Private Placement of Common Stock and Preliminary Unaudited Financial Results for the Fourth Quarter and Fiscal Year 2024

January 14
Last Trade: 2.93 -0.19 -6.09

NATICK, Mass. / Jan 14, 2025 / Business Wire / Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has entered into a subscription agreement with funds affiliated with RTW Investments, LP (“RTW”) for the purchase and sale of 841,751 shares of the Company’s common stock in a private placement at a purchase price of $2.97 per share. The private placement is...Read more


NuGen Medical Devices Announces the Appointment of Liang Lin as Chief Executive Officer

January 14
Last Trade: 0.08 -0.005 -5.88

Toronto, Ontario--(Newsfile Corp. - January 14, 2025) - NuGen Medical Devices Inc. (TSXV: NGMD) (the "Company" or "NuGen") a leading developer of needle-free devices to administer therapeutics subcutaneously, is pleased to announce the appointment of Mr. Liang Lin as the new Chief Executive Officer of NuGen. Liang is the founder and CEO of Sol-Millennium Medical Group ("SolM"), an organization committed to transforming the medical device...Read more


Merit Medical Systems Announces Preliminary Unaudited Revenue for the Year Ended December 31, 2024 and Plans to Announce Fourth Quarter and Year End 2024 Results and Issue Fiscal Year 2025 Guidance on February 25, 2025

January 13
Last Trade: 102.90 0.83 0.81

2024 preliminary unaudited revenue in the range of approximately $1.355 billion - $1.357 billion, up approximately 7.7% - 7.9% year-over-year 2024 preliminary constant currency revenue* increased in the range of approximately 8.4% - 8.6% year over year 2024 financial results and 2025 guidance to be released February 25, 2025 * Constant currency revenue is a non-GAAP financial measure. A reconciliation of this financial measure...Read more


Patient Reported Outcomes for GRAIL's Galleri® Multi-Cancer Early Detection Blood Test Published in Lancet Oncology

January 13
Last Trade: 17.42 0.02 0.11

Analysis of Patient Reported Outcomes From PATHFINDER Indicate Minimal Patient Distress Associated with Multi-Cancer Early Detection Testing MENLO PARK, Calif., Jan. 13, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL) a healthcare company whose mission is to detect cancer early when it can be cured, today announced that patient-reported outcomes (PRO) assessing patient perspectives from the PATHFINDER study were published in Lancet...Read more


Medtronic announces CMS national coverage analysis for Symplicity™ Spyral Renal Denervation System

January 13
Last Trade: 88.08 0.92 1.06

National coverage analysis is the first-of-its kind for a minimally invasive, interventional treatment for high blood pressure Milestone is supported by large public health need and robust, long-term data from the SPYRAL-HTN global clinical program GALWAY, Ireland, Jan. 13, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that the Centers for Medicare & Medicaid...Read more


Insulet Launches Revolutionary Omnipod® 5 in Five More Countries in Europe

January 13
Last Trade: 275.81 2.95 1.08

The Omnipod 5 Automated Insulin Delivery System is now commercially available in Italy, Denmark, Finland, Norway, and Sweden with Abbott’s FreeStyle Libre 2 Plus and Dexcom G6 ACTON, Mass. / Jan 13, 2025 / Business Wire / Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the Omnipod 5 Automated Insulin Delivery System...Read more


Inogen Announces Preliminary Fourth Quarter and Full Year 2024 Revenue

January 13
Last Trade: 10.47 -0.05 -0.48

GOLETA, Calif. / Jan 13, 2025 / Business Wire / Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced unaudited preliminary revenue results for the fourth quarter and the full year ended December 31, 2024. The Company estimates preliminary, unaudited total revenue in the fourth quarter of 2024 to be in the range of $79.0 million to $80.0 million,...Read more


OrthoPediatrics Achieves Record Preliminary Unaudited Revenue for Full Year 2024 and Issues 2025 Financial Guidance

January 13
Last Trade: 27.16 0.63 2.37

Achieves all-time high full year 2024 Revenue of $205 million representing growth of 38% Year-Over-Year Initiates guidance for record adjusted EBITDA in 2025 WARSAW, Ind., Jan. 13, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced preliminary unaudited financial highlights for the fourth...Read more


Accuray Announces China National Medical Products Administration Approval of the Radixact® SynC™ and CyberKnife® S7™ Systems; Expands on the China Product Portfolio that Includes the Recently Approved Tomo® C System

January 13
Last Trade: 2.24 -0.06 -2.61

MADISON, Wis., Jan. 13, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the company's Radixact SynC™ System and CyberKnife® S7™ System have been approved by the Chinese National Medical Products Administration (NMPA). With these approvals medical care teams can provide patients in China the most advanced Accuray radiation therapy solutions. The CyberKnife S7 System is the latest generation CyberKnife platform...Read more


Alphatec Announces Select Preliminary Financial Results for 2024 and Provides 2025 Outlook

January 13
Last Trade: 11.57 0.28 2.48

Full-year 2024 total revenue grew 27% to approximately $611 million Expect full-year 2025 total revenue of $732 million and positive free cash flow CARLSBAD, Calif. / Jan 13, 2025 / Business Wire / Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today preliminary financial results for the fourth quarter and full-year ended December 31,...Read more


SI-BONE Announces Preliminary Revenue for the Fourth Quarter and Full Year 2024

January 13
Last Trade: 16.69 -0.23 -1.36

Fourth Quarter 2024 worldwide revenue of ~$48.8 to $49.0 million representing growth of ~26% Achieved adjusted EBITDA profitability in the fourth quarter SANTA CLARA, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced its preliminary and unaudited revenue and cash and cash equivalents for fourth quarter and full year...Read more


BioLife Solutions Announces Preliminary Fourth Quarter and Full Year 2024 Unaudited Revenue from Continuing Operations

January 13
Last Trade: 26.14 -0.31 -1.17

Fourth quarter Cell Processing revenue increased 7% sequentially to $20.3 million Unaudited revenue for FY2024 from Cell Processing of $73.5 million, exceeded the high end of previously raised guidance BOTHELL, Wash., Jan. 13, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction products and services for the cell and gene therapy (CGT)...Read more


Nevro Announces Preliminary Fourth-Quarter and Full-Year 2024 Revenue Results

January 13
Last Trade: 4.57 0.07 1.56

Cash, Cash Equivalents and Short-Term Investments Increased Approximately $15.5 million in the Fourth Quarter of 2024 REDWOOD CITY, Calif., Jan. 13, 2025  /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced its preliminary, unaudited fourth-quarter and full-year 2024 revenue and other financial...Read more


FDA Approves Feasibility Study with SeaStar Medical’s Selective Cytopheretic Device in Adults with Cardiorenal Syndrome

January 13
Last Trade: 1.75 0.04 2.34

Study to be conducted under $3.6 million NIH grant  DENVER, Jan. 13, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that the U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) application to evaluate the...Read more


Butterfly Network and Rutgers Robert Wood Johnson Medical School Reveal Preliminary Findings from Seminal Study on Impact of POCUS in Hospital Care

January 13
Last Trade: 3.67 -0.21 -5.41

Study demonstrates significant reductions in length of stay and healthcare costs, advocating for broader adoption of POCUS in hospital settings. BURLINGTON, Mass. & NEW YORK / Jan 13, 2025 / Business Wire / Butterfly Network, Inc. (“Butterfly”, “the Company”) (NYSE: BFLY), a digital health company transforming care with handheld, whole-body ultrasound today announced preliminary findings from a seminal study conducted by Rutgers...Read more


AngioDynamics Announces Publication of APEX-AV Trial Results in JSCAI

January 13
Last Trade: 12.43 -0.34 -2.66

Peer-reviewed data highlights successful clinical study with 35.5% clot burden reduction, validating the safety, efficacy, and efficiency of AlphaVac F1885 System in pulmonary embolism treatment. LATHAM, N.Y. / Jan 13, 2025 / Business Wire / AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options...Read more


Paragon 28 Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2024

January 13
Last Trade: 10.88 0.22 2.06

ENGLEWOOD, Colo. / Jan 13, 2025 / Business Wire / Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or “P28”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced a range of its preliminary unaudited net revenue for the fourth quarter and full year ended December 31, 2024. Preliminary unaudited net revenue for the fourth quarter of 2024 is expected to be in a range of $71.5 to $71.8...Read more


AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2024, Provides Financial Outlook for 2025, and Announces Upcoming Analyst & Investor Day

January 13
Last Trade: 38.47 0.83 2.21

MASON, Ohio / Jan 13, 2025 / Business Wire / AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced preliminary financial results for the fourth quarter and full year 2024 and provided 2025 financial guidance. Additionally, AtriCure announced that it will host an Analyst & Investor...Read more


Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results

January 13
Last Trade: 14.33 0.66 4.83

Fourth Quarter Revenue Approximately $15.1 Million and Full Year Total Revenue Approximately $37.2 Million QUEENSBURY, N.Y. / Jan 13, 2025 / Business Wire / Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced preliminary financial results for the fourth quarter and year-ended December 31,...Read more


KORU Medical Systems Reports Preliminary Fourth Quarter and Full Year 2024 Results; Achieves Record Full Year and Quarterly Revenues; Positive Cash Flow for the Fourth Quarter

January 13
Last Trade: 4.08 0.08 2.00

MAHWAH, N.J. / Jan 13, 2025 / Business Wire / KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced preliminary unaudited results for the fourth quarter and full year ended December 31, 2024. Financial Results...Read more


Ekso Bionics Reports Certain Preliminary Fourth Quarter 2024 Financial Results

January 13
Last Trade: 0.65 -0.04 -5.64

Expects Record Revenues for the Fourth Quarter of 2024 SAN RAFAEL, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced preliminary top line financial results for the quarter ended December 31, 2024. Total revenue for the fourth quarter of 2024 is estimated to be in the range of $5.0 million...Read more


Treace Medical Concepts Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2024 Revenue

January 13
Last Trade: 8.71 0.46 5.58

PONTE VEDRA, Fla., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced its preliminary, unaudited fourth quarter and full-year 2024...Read more


CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2024 Financial Results and Issues Fiscal 2025 Guidance

January 13
Last Trade: 17.62 0.32 1.85

Fourth quarter revenue expected to be $15.2 million to $15.3 million, representing growth of 35% Full year revenue expected to be $51.1 million to $51.2 million, representing growth of 30% Fiscal 2025 revenue expected to be between $63.0 million and $65.0 million, representing growth of 23% to 27% MINNEAPOLIS, Jan. 13, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today...Read more


Apyx Medical Reports Preliminary Fourth Quarter and Full Year 2024 Revenue Results

January 13
Last Trade: 1.39 -0.03 -2.11

CLEARWATER, Fla, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today reported preliminary revenue results for the fourth quarter and full year ended December 31, 2024. Preliminary Fourth Quarter 2024 Revenue Summary Total revenue expected to be in a range of approximately $14.1 to...Read more


Pulse Biosciences’ Nanosecond PFA Technology to be Featured in Multiple Presentations at the AF Symposium

January 13
Last Trade: 17.61 -0.03 -0.17

Nanosecond PFA 360° Cardiac Catheter for AF ablation to be highlighted in late-breaking clinical science session and in a live case transmission MIAMI / Jan 13, 2025 / Business Wire / Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced that its nsPFA technology will be featured in a late-breaking science session and a live case...Read more


Bausch + Lomb Bolsters Pipeline with Acquisition of Whitecap Biosciences

January 13
Last Trade: 17.40 -0.04 -0.23

VAUGHAN, Ontario / Jan 13, 2025 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced an affiliate has acquired Whitecap Biosciences, LLC, which is currently developing two innovative therapies for potential use in glaucoma and geographic atrophy (GA). The acquisition strengthens Bausch + Lomb’s expanding clinical-stage...Read more


Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update

January 13
Last Trade: 26.17 0.15 0.58

Preliminary full year 2024 net revenues of $605 million and fourth quarter net revenues of $161 million Novocure to present at the 43rd Annual J.P. Morgan Healthcare Conference at 9:00 a.m. PST on Wednesday, January 15, 2025 BAAR, Switzerland / Jan 13, 2025 / Business Wire / Novocure (NASDAQ: NVCR) today reported preliminary unaudited financial and operational results for the quarter and full year ended December 31, 2024. Novocure is...Read more


EDAP TMS Announces Preliminary Record Fourth Quarter Focal One® System Sales and Record U.S. Procedures

January 13
Last Trade: 2.17 -0.03 -1.36

Company Reports Preliminary Worldwide Record Fourth Quarter Sales of 11 Focal One Systems  Record U.S. Fourth Quarter Focal One System Sales Record Number of U.S. Focal One Procedures, with Year-Over-Year Growth of 30% AUSTIN, Texas, January 13, 2025 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company” or “EDAP”), the global leader in robotic energy-based therapies, today announced preliminary record Focal One System sales for the...Read more


Inspire Medical Systems Announces Preliminary Results for the Fourth Quarter and Full Year 2024 and Provides Initial 2025 Revenue Guidance

January 13
Last Trade: 177.68 3.85 2.21

MINNEAPOLIS, Minn, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”, or the “Company”), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today announced certain preliminary, unaudited results for the fourth quarter and full year ended December 31, 2024, and provided its initial full...Read more


Bausch + Lomb Launches enVista Aspire™ Intermediate Optimized Monofocal and Toric Intraocular Lenses in the European Union

January 13
Last Trade: 17.40 -0.04 -0.23

VAUGHAN, Ontario / Jan 13, 2025 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the commercial launch of the enVista Aspire monofocal and toric intraocular lenses (IOLs) in the European Union after receiving a CE Mark late last year. enVista Aspire combines novel Intermediate Optimized optics, which are designed for a...Read more


MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results

January 13
Last Trade: 4.94 0.19 4.00

ROCKVILLE, Md., Jan. 13, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today provided a preliminary update on financial results for the fourth quarter and full year ended December 31, 2024. Preliminary Unaudited Fourth Quarter and Full...Read more


CytoSorbents Strengthens Balance Sheet with Closing of Oversubscribed Rights Offering

January 13
Last Trade: 1.03 -0.01 -0.96

Oversubscribed Rights Offering Generated $6.25 Million in Aggregate Gross Proceeds Offering Proceeds Satisfies Debt Covenant, Unlocking $5.0 Million in Restricted Cash Currently on the Balance Sheet PRINCETON, N.J., Jan. 13, 2025 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announced today...Read more


Medtronic achieves CE Mark approval for BrainSense™ Adaptive deep brain stimulation and Electrode Identifier, a groundbreaking advance in personalized, sensing-enabled care for people with Parkinson's through innovative brain-computer interface technology...

January 13
Last Trade: 88.08 0.92 1.06

European approval introduces the world's only closed-loop DBS system with real-time, self-adjusting brain stimulation for people with Parkinson's disease GALWAY, Ireland, Jan. 13, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, announced today CE (Conformité Européenne) Mark approval in the European Union (EU) and the United Kingdom (UK) for BrainSense™ Adaptive deep brain stimulation (aDBS)...Read more


Microbot Medical Strengthens Its Commercial Capabilities with the Addition of David J. Wilson to the Board of Directors

January 13
Last Trade: 1.64 -0.14 -7.87

BRAINTREE, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, is continuing its transition into a commercially focused company with the election of David J. Wilson to the Board of Directors. Mr. Wilson is a seasoned healthcare executive with a background of commercial success and revenue growth in the endovascular devices market. Mr. Wilson’s...Read more


Tactile Medical Appoints Laura King to Board of Directors

January 13
Last Trade: 17.40 -0.03 -0.17

MINNEAPOLIS, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced the appointment of Laura King to the Company’s Board of Directors (“Board”) and as a member of the Audit and Compliance & Reimbursement Committees, effective January 13, 2025. Ms. King is a seasoned healthcare executive...Read more


Establishment Labs Announces CEO Transition

January 13
Last Trade: 34.56 -0.08 -0.23

Peter Caldini to become Interim CEO effective March 1, 2025 Establishment Labs also announces preliminary unaudited fourth quarter revenue in line with recent guidance NEW YORK / Jan 13, 2025 / Business Wire / Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness in breast aesthetics and reconstruction, announced today that after twenty years as Chief...Read more


Hologic Announces Preliminary Revenue Results for First Quarter of Fiscal 2025

January 12
Last Trade: 69.73 -0.24 -0.34

Revenue of $1,021.8 Million Grows 0.9%  Revenue Increases 1.0% on Constant Currency Basis, In-Line with Guidance GAAP and Non-GAAP EPS Expected to be Near High End of Guidance Ranges MARLBOROUGH, Mass. / Jan 12, 2025 / Business Wire / Hologic, Inc. (Nasdaq: HOLX) announced today preliminary revenue results for its first fiscal quarter ended December 28, 2024. The Company expects to report total revenues of approximately...Read more


RxSight Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Financial and Operational Results and 2025 Guidance

January 12
Last Trade: 30.39 -0.79 -2.53

ALISO VIEJO, Calif., Jan. 12, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced certain preliminary unaudited financial and operational results for the fourth quarter and full-year 2024 and provided full-year 2025 guidance. Preliminary Unaudited Fourth Quarter and Full-year 2024...Read more


Microbot Medical Closes $8.6 Million Registered Direct Offering

January 10
Last Trade: 1.64 -0.14 -7.87

BRAINTREE, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 3,788,550 shares of the Company’s common stock at a purchase price of $2.27 per share of common stock. In addition, in a concurrent private placement, the Company issued unregistered short-term series...Read more


IRadimed Reports Preliminary Unaudited Record Fourth Quarter and Full-Year 2024 Revenues

January 10
Last Trade: 59.17 0.81 1.39

Reports preliminary fourth quarter 2024 revenue in the range of approximately $19.2 million to $19.4 million Reports preliminary full-year 2024 revenue in the range of approximately $73.1 million to $73.3 million Iradimed is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15th, 2025, at 5:15 p.m. PT  WINTER SPRINGS, Fla., Jan. 10, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”...Read more


NeuroOne Medical Technologies Announces Preliminary Unaudited First Quarter Fiscal 2025 Revenue Increase to a Record $6.2 Million

January 10
Last Trade: 1.06 0.02 1.91

First Quarter Fiscal 2025 Revenue Includes a One-Time Upfront Payment of $3.0 Million in Collaboration Revenue from Zimmer Biomet and $3.2M in Product Revenue Management to Host Virtual Investor Webinar Today at 11:00 a.m. Eastern Time EDEN PRAIRIE, Minn., Jan. 10, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving...Read more


Pulse Biosciences Appoints Paul LaViolette as Chief Executive Officer

January 10
Last Trade: 17.61 -0.03 -0.17

Current Co-Chairman of the Board will now also serve as Chief Executive Officer MIAMI / Jan 10, 2025 / Business Wire / Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced the appointment of Paul A. LaViolette, current Co-Chairman of the Board, as Chief Executive Officer. "We are...Read more


Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2024

January 10
Last Trade: 18.09 -0.34 -1.84

ALACHUA, Fla. and TAMPA, Fla., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced preliminary unaudited fourth quarter and full-year 2024 key financials. Preliminary Fourth Quarter and Year-End Key Business Highlights Fourth quarter revenue is expected to be approximately $49.4 million, which represents...Read more


Quanterix to Acquire Akoya Biosciences, Creating the First Integrated Solution for Ultra-Sensitive Detection of Blood- and Tissue-Based Protein Biomarkers

January 10
Last Trade: 8.87 0.05 0.57

Complementary offerings will accelerate translation of biomarkers from research to the clinic driving new growth Expanded customer relationships and continuum of solution offerings maximize cross-selling opportunities across translational, academic and pharma applications Expects to generate approximately $40 million of annual cost synergies by the end of 2026 with path to positive free cash flow generation in 2026 Combined cash...Read more


Perspective Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 10
Last Trade: 3.43 0.27 8.54

SEATTLE, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that Thijs Spoor, Chief Executive Officer, will present at the 43nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on Wednesday, January 15, 2025, at 3:45 p.m. PT....Read more


Inspira Technologies Preparing Production in Response to Spread of Respiratory Virus in China

January 10
Last Trade: 1.06 0.00 0.00

RA'ANANA, Israel, Jan. 10, 2025 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) ("Inspira" or the "Company"), a leader in life-support technology innovation, announced today that it is preparing for a potential production ramp-up of its INSPIRA™ ART100 device. This strategic readiness comes in light of the recent outbreak of human metapneumovirus (hMPV) in China, which has highlighted the growing...Read more


EDAP TMS Appoints Joshua H. Levine to Board of Directors

January 10
Last Trade: 2.17 -0.03 -1.36

AUSTIN, Texas, January 10, 2025 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company” or “EDAP”), the global leader in robotic energy-based therapies, today announced the appointment of Joshua H. Levine to its Board of Directors.  “We are pleased to welcome Josh Levine to our Board of Directors," said Dr. Lance Willsey, Interim Chairman of the Board of EDAP TMS. “Josh brings a wealth of executive experience and a track record of growing...Read more


TriSalus Life Sciences® Announces Publication of Pre-Clinical Data Demonstrating Improved Delivery of Embospheres® to Liver Tumors using Pressure-Enabled Drug Delivery™ (PEDD™) via the TriNav® Infusion System

January 9
Last Trade: 4.93 0.10 2.07

DENVER / Jan 09, 2025 / Business Wire / TriSalus Life Sciences®, Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), TriSalus Life Sciences seeks to transform outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care therapies and our investigational immunotherapy, announced today the publication of research titled, “Pressure Enabled Drug Delivery (PEDD) Significantly Increases...Read more


Masimo to Present in the 43rd Annual J.P. Morgan Healthcare Conference

January 9
Last Trade: 172.29 2.35 1.38

IRVINE, Calif. / Jan 09, 2025 / Business Wire / Masimo (NASDAQ: MASI) today announced that its management will participate in the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025 at 10:30 a.m. Pacific time. A live webcast of the presentation will be available on the Masimo website at www.masimo.com. A replay of the webcast will be available following the live presentation. About Masimo Masimo (NASDAQ: MASI) is a...Read more


Teleflex awarded Short Term Central Venous Catheters contract from Vizient

January 9
Last Trade: 181.27 -0.18 -0.10

WAYNE, Pa., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it has been awarded a contract by Vizient, Inc., the largest provider-driven healthcare performance improvement company in the U.S. The agreement, effective January 1, 2025, covers the supply of Teleflex’s Central Venous Access Catheters and Arterial Catheters. Vizient provides solutions and...Read more


Senseonics Announces Business Updates Including Preliminary 2024 Results, 365 Launch Update and Cancellation of Special Meeting

January 8
Last Trade: 0.85 -0.03 -3.09

GERMANTOWN, Md., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced operational, financial and other business updates. Recent Highlights & Accomplishments Generated preliminary unaudited fourth quarter revenue of...Read more


Globus Medical Reports Preliminary Record Fourth Quarter and Full Year Sales Results

January 8
Last Trade: 90.80 0.33 0.36

AUDUBON, Pa., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced preliminary unaudited sales results for the fourth quarter and full year ending December 31, 2024. The company anticipates fourth quarter 2024 sales of approximately $657.0 million, an increase of 6.6 percent over the fourth quarter 2023 on an as-reported basis. Full year 2024 sales are expected...Read more


NeuroPace Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2024 and Provides Business Updates

January 8
Last Trade: 11.97 0.06 0.50

Preliminary unaudited revenue expected to be between $21.0 million and $21.5 million for Q4 2024, and between $79.4 million and $79.9 million for full year 2024 Scott Huennekens Appointed to NeuroPace Board of Directors effective January 6th Management presenting at the 43rd Annual J.P. Morgan Healthcare Conference on January 15th Company to host an Investor Day on January 28th in New York City...Read more


Outset Medical to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 8
Last Trade: 0.79 -0.03 -3.45

SAN JOSE, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that Chair & CEO Leslie Trigg will present at the 43rd annual J.P. Morgan Healthcare conference on Wednesday, January 15, 2025, at 8:15 a.m. Pacific time. A live and archived webcast of the presentation...Read more


Allurion Technologies Announces Positive Topline Results From AUDACITY Trial

January 8
Last Trade: 2.93 -0.19 -6.09

At 48 weeks, Allurion Balloon subjects had a greater than 50% responder rate and substantially greater weight loss than Control subjects Low rate of serious adverse events supports favorable safety profile of the Allurion Balloon Fourth and final module of PMA submission including AUDACITY trial data planned for 2025 NATICK, Mass.--(BUSINESS WIRE)-- Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending...Read more


Movano Health Launches EvieAI Virtual Wellness Assistant

January 8
Last Trade: 5.63 2.52 81.03

Newest Evie Ring feature is the first medical journal trained AI companion in a wearable PLEASANTON, Calif., Jan. 8, 2025 /PRNewswire/ -- Movano Health (Nasdaq: MOVE) today announced the latest enhancement to its Evie smart ring for women with the beta release of EvieAI, the first wearable-based virtual wellness assistant trained exclusively with data from medical journals. The new feature enables Evie users to answer...Read more


Bruker Launches Infrared Imaging Microscope for Pharma and Life Science Research

January 8
Last Trade: 56.88 -2.13 -3.61

Groundbreaking LUMOS II ILIM QCL-based IR microscope sets new standards in speed and resolution BILLERICA, Mass.--(BUSINESS WIRE)-- Bruker Corporation (Nasdaq: BRKR) today announced the launch of the LUMOS™ II ILIM, a quantum cascade laser (QCL) based infrared imaging microscope. The new LUMOS II ILIM redefines performance standards, enabling pharma and life science researchers to capture ultrafast IR images of expansive...Read more


Butterfly Network Reports Preliminary, Unaudited Fourth Quarter 2024 Revenue Growth of Approximately 35% Year over Year

January 8
Last Trade: 3.67 -0.21 -5.41

Butterfly Network Reports Preliminary, Unaudited Fourth Quarter 2024 Revenue Growth of Approximately 35% Year over Year BURLINGTON, Mass & NEW YORK--(BUSINESS WIRE)-- Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly”, “the Company”), a digital health company transforming care with portable, semiconductor-based ultrasound technology and intuitive software, today announced that it expects to report revenue growth for the...Read more


Profound Medical Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Revenues

January 8
Last Trade: 7.35 -0.08 -1.08

Fourth quarter revenue growth estimated at 105% to 110% year-over-year  Company to start reporting in accordance with U.S. GAAP and filing with the SEC on U.S. domestic forms  Profound reminds investors that it is scheduled to present at JPM 2025 on January 16th at 11:15 a.m. PT  TORONTO, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage...Read more


Boston Scientific Announces Agreement to Acquire Bolt Medical

January 8
Last Trade: 98.66 0.49 0.50

Acquisition to expand cardiovascular portfolio with complementary and differentiated calcium modification platform, furthering company's strategy to address coronary and peripheral disease MARLBOROUGH, Mass., Jan. 8, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Bolt Medical, Inc., the developer of an intravascular lithotripsy (IVL) advanced...Read more


EDAP TMS Announces First Pancreatic Cancer Patient Treated with Proprietary HIFU Technology

January 8
Last Trade: 2.17 -0.03 -1.36

AUSTIN, Texas, January 8, 2025 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that the first patient has been treated in a phase I/II PULS Trial sponsored by the Centre Léon Bérard, Lyon, France, evaluating proprietary High Intensity Focused Ultrasound (HIFU) technology for the treatment of pancreatic tumors. “The initiation of the PULS Trial represents a major milestone in efforts to...Read more


Microbot Medical Announces $8.6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

January 8
Last Trade: 1.64 -0.14 -7.87

HINGHAM, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has entered into definitive agreements for the purchase and sale of 3,788,550 shares of the Company’s common stock at a purchase price of $2.27 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue unregistered...Read more


Lifeward Announces Closing of $5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

January 8
Last Trade: 1.64 -0.17 -9.39

MARLBOROUGH, Mass. and YOKNEAM ILIT, Israel, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global market leader delivering life-changing solutions to revolutionize what is possible in rehabilitation, recovery, and the pursuit of life’s passions in the face of physical limitation or disability, today announced the closing of its previously announced registered direct offering priced...Read more


AVITA Medical Updates Expected Fourth Quarter and Full Year 2024 Revenue, Provides 2025 Financial Guidance

January 7
Last Trade: 8.65 0.11 1.29

VALENCIA, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced an update to its fourth quarter and full-year 2024 commercial revenue guidance. For the quarter ended December 31, 2024, AVITA Medical now expects commercial revenue to be approximately $18.4...Read more


Sight Sciences Announces Real-World 36-Month Study Confirming Long-Term Effectiveness of Standalone OMNI Surgical System in Managing Primary Open-Angle Glaucoma

January 7
Last Trade: 2.83 -0.01 -0.35

MENLO PARK, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today announced the publication of a landmark 36-month analysis evaluating the long-term effectiveness of the OMNI® Surgical System (“OMNI”) in...Read more


Rapid Micro Biosystems to Present at 43ʳᵈ Annual J.P. Morgan Healthcare Conference

January 7
Last Trade: 1.23 0.03 2.50

LEXINGTON, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference. The Company is scheduled to present on...Read more


OraSure Technologies to Present at the J.P Morgan Healthcare Conference

January 7
Last Trade: 3.65 -0.07 -1.88

BETHLEHEM, Pa., Jan. 07, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced that members of its management team will participate in the 43rd Annual J.P. Morgan Healthcare Conference. OraSure’s presentation is scheduled for Thursday, January 16, 2025 at 9:00 a.m. PT. A live webcast and replay of the presentation will be...Read more


Tandem Diabetes Care Enters Multi-Year Research Collaboration with UVA Center for Diabetes Technology for Development of Advanced Insulin Delivery Systems

January 7
Last Trade: 35.15 -2.38 -6.34

SAN DIEGO--(BUSINESS WIRE)-- Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced it has signed a multi-year collaboration agreement with the University of Virginia Center for Diabetes Technology (UVA) to advance research and development efforts on fully automated closed-loop insulin delivery systems. The research collaboration will rely on the UVA Center for Diabetes...Read more


NanoVibronix Advances Development of PainShield and UroShield with Completion of NextGen Prototypes

January 7
Last Trade: 0.50 -0.02 -3.81

Development advancing to verification and testing phase; Aims to future-proof design, lower componentry costs and improve manufacturing ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc. (NASDAQ: NAOV) (the “Company”), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced a third-party contractor engaged by the...Read more


Inspira Technologies Flagship Technology to be Showcased at Arab Health Expo 2025 in Dubai

January 7
Last Trade: 1.06 0.00 0.00

Visitors at Glo-Med Network Inc's booth can explore Inspira's cutting-edge respiratory solutions, with the FDA-cleared INSPIRA™ ART100, showcasing the future of respiratory care RA'ANANA, Israel, Jan. 7, 2025 /PRNewswire/ -- Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN) (NASDAQ: IINNW), ("Inspira Technologies," "Inspira" or the "Company"), a groundbreaking respiratory support technology company, is pleased to...Read more


electroCore Expands Intellectual Property Portfolio

January 7
Last Trade: 15.90 0.20 1.27

ROCKAWAY, N.J., Jan. 07, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it has received five patent issue notifications from the United States Patent and Trademark Office (USPTO). The five patents have been issued between December 17, 2024, and December 31, 2024: US Patent No. 12,168,128 entitled “Systems and Methods for Treating a Medical...Read more


Bioventus to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 7
Last Trade: 10.04 -0.07 -0.69

DURHAM, N.C., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Rob Claypoole, chief executive officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 10:30 a.m. PT (1:30 p.m. ET). The live webcast of the presentation, including Q&A, may be accessed on the Investors section of the Bioventus...Read more


Repligen to Present at 43rd Annual J.P. Morgan Healthcare Conference

January 7
Last Trade: 160.51 -2.34 -1.44

WALTHAM, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate in the 43rd Annual J.P. Morgan Healthcare Conference, being held January 13 – 16 in San Francisco. Olivier Loeillot, President and Chief Executive Officer, will present an overview of the company on Tuesday, January 14 at 1:30 p.m. PT. A live...Read more


Sign Up To Get Daily
Life Science News

Please review our Disclaimer and Privacy Policy before subscribing.

Medical Device Gainers

 
CompanyChangeLast Trade
Intuitive Surgical 8.56 1.47 $592.64
Semler Scientific 6.44 11.06 $64.68
Inspire Medical Systems 3.85 2.21 $177.68
Sonendo 3.27 1,421.74 $3.50
Insulet 2.95 1.08 $275.81
ResMed 2.65 1.12 $239.78
Movano Health 2.52 81.03 $5.63
Masimo 2.35 1.38 $172.29
Stryker 1.63 0.43 $383.42
Vicarious Surgical 1.59 11.15 $15.85
Penumbra 1.38 0.53 $263.69
iRhythm Technologies 1.34 1.25 $108.33
CooperCompanies 1.23 1.34 $93.27
Becton Dickinson 1.08 0.46 $237.38
Medtronic 0.92 1.06 $88.08

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE